Trials / Withdrawn
WithdrawnNCT01214291
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- GTx · Industry
- Sex
- Male
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Toremifene | Toremifene 80mg daily |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-10-05
- Last updated
- 2013-11-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01214291. Inclusion in this directory is not an endorsement.